Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma

Adolescents (12–17 years of age) with severe eosinophilic asthma experience frequent exacerbations and reduced lung function leading to poor health-related quality of life. Mepolizumab is approved for add-on maintenance therapy in patients with severe eosinophilic asthma ≥ 6 years of age in the EU a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yancey, Steven W., Ortega, Hector G., Keene, Oliver N., Bradford, Eric S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724286/
https://www.ncbi.nlm.nih.gov/pubmed/31507641
http://dx.doi.org/10.1186/s13223-019-0366-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724286/
https://www.ncbi.nlm.nih.gov/pubmed/31507641
http://dx.doi.org/10.1186/s13223-019-0366-x

Ejemplares similares